Payment overview · 2025
General Payments
$683.05
29 reported records · 15 companies
Healthcare provider profile · identity verified
Sara W Wallace, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CUMMING, GA · NPI 1114464310
Verified facts
What the public records show
CMS Open Payments records show Sara W Wallace, NP-C received $683.05 in general payments during 2025 across 29 reported records.
Dexcom, Inc. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $144.72 | 21.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.06 | 12.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.93 | 9.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.09 | 8.8% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $50.86 | 7.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.50 | 6.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.70 | 6.4% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $36.02 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.26 | 3.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.95 | 3.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.85 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.54 | 3.3% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $21.65 | 3.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.41 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.51 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.05 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $144.72 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.16 | 3 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $50.86 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.81 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.81 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.50 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $43.70 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $36.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.54 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 222 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 203 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 40 |
| Lisinopril | Lisinopril | 105 | 39 |
| Metformin Hcl | Metformin Hcl | 102 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 33 |
| Trazodone Hcl | Trazodone Hcl | 86 | 28 |
| Simvastatin | Simvastatin | 83 | 28 |
| Losartan Potassium | Losartan Potassium | 76 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 66 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 27 |
| Ozempic | Semaglutide | 64 | 11 |
| Montelukast Sodium | Montelukast Sodium | 63 | 27 |
| Omeprazole | Omeprazole | 62 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 19 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Gabapentin | Gabapentin | 55 | 22 |
| Methylprednisolone | Methylprednisolone | 54 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 50 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 19 |
| Bupropion Xl | Bupropion Hcl | 44 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 34 |
| Meloxicam | Meloxicam | 42 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Sertraline Hcl | Sertraline Hcl | 40 | 21 |
| Carvedilol | Carvedilol | 39 | 12 |
| Jardiance | Empagliflozin | 39 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 35 |
| Buspirone Hcl | Buspirone Hcl | 38 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 36 | 15 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Alprazolam | Alprazolam | 33 | 14 |
| Famotidine | Famotidine | 32 | 13 |
| Fluconazole | Fluconazole | 30 | 14 |
| Furosemide | Furosemide | 30 | 12 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 22 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Atenolol | Atenolol | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 18 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 17 |
| Azithromycin | Azithromycin | 16 | 14 |
| Cephalexin | Cephalexin | 16 | 14 |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 13 |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $683.05 · 29 records | Dexcom, Inc. | Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, EVENITY, FARXIGA, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, PAXLOVID, QULIPTA, REPATHA, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VITALPATCH RTM, WaveWriter Alpha Prime 16, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error